Aranidipine | CAS# 86780-90-7 | Calcium Channel Blocker

MedKoo Cat#: 573261 | Name: Aranidipine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aranidipine is a calcium channel blocker which may positively affect ambulatory blood pressure.

Chemical Structure

Aranidipine

CAS#86780-90-7

Theoretical Analysis

MedKoo Cat#: 573261

Name: Aranidipine

CAS#: 86780-90-7

Chemical Formula: C19H20N2O7

Exact Mass: 388.1271

Molecular Weight: 388.38

Elemental Analysis: C, 58.76; H, 5.19; N, 7.21; O, 28.84

Price and Availability

Size	Price	Availability
50mg	USD 350.00	2 Weeks
100mg	USD 550.00	2 Weeks
200mg	USD 950.00	2 Weeks
500mg	USD 2,050.00	2 Weeks
1g	USD 3,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Aranidipine, CCRIS 6724; CCRIS-6724; CCRIS6724; MPC 1304; MPC-1304; MPC1304;

IUPAC/Chemical Name

(+-)-Acetonyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate

InChi Key

NCUCGYYHUFIYNU-UHFFFAOYSA-N

InChi Code

1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3

SMILES Code

CC(COC(C1=C(C)NC(C)=C(C(OC)=O)C1C2=C([N+]([O-])=O)C=CC=C2)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 388.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jiao Y, Chen L, Zheng JT, Ke YN, Wang Y, Yang HY, Jin H, Zhao XL, Liu MX, Wang L, Wang BY, Li DY. [Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension]. Zhonghua Yi Xue Za Zhi. 2013 Oct 22;93(39):3104-10. Chinese. PMID: 24417987. 2: Yan LR, Li YS, Chen GL, Wang L, Pang HM, Wu SY, Yu J, Li HM, Lin YZ, Zhao RP, Fan CM. Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial. J Cardiovasc Pharmacol. 2012 Jul;60(1):8-14. doi: 10.1097/FJC.0b013e318254a566. PMID: 22441301. 3: Nakamura A, Hayashi K, Fujiwara K, Ozawa Y, Honda M, Saruta T. Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection. J Cardiovasc Pharmacol. 2000 Jun;35(6):942-8. doi: 10.1097/00005344-200006000-00018. PMID: 10836731. 4: Miyoshi K, Miyake H, Ichihara K, Kamei H, Nagasaka M. Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jan;355(1):119-25. doi: 10.1007/pl00004909. PMID: 9007851. 5: Chen L, Jiang H, Hua Q, Yang HY, Zheng JT, Jin H, Jiao Y, Wang Y, Sun RH, Ke YN. [The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension]. Zhonghua Nei Ke Za Zhi. 2013 Sep;52(9):749-52. Chinese. PMID: 24314165. 6: Masumiya H, Tanaka Y, Tanaka H, Shigenobu K. Inhibition of T-type and L-type Ca(2+) currents by aranidipine, a novel dihydropyridine Ca(2+) antagonist. Pharmacology. 2000 Aug;61(2):57-61. doi: 10.1159/000028381. PMID: 10940777. 7: Jiang J, Tian L, Huang Y, Li Y, Xu L. Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple- dose study. Clin Ther. 2008 Jul;30(7):1290-9. doi: 10.1016/s0149-2918(08)80053-7. PMID: 18691988. 8: Ichihara K, Okumura K, Kamei H, Nagasaka M, Kanda A, Kanno T, Miyoshi K, Miyake H. Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1998 Feb;31(2):277-85. doi: 10.1097/00005344-199802000-00014. PMID: 9475270. 9: Okumura K, Ichihara K, Nagasaka M. Effects of aranidipine, a novel calcium channel blocker, on mechanical responses of the isolated rat portal vein: comparison with typical calcium channel blockers and potassium channel openers. J Cardiovasc Pharmacol. 1997 Feb;29(2):209-15. doi: 10.1097/00005344-199702000-00009. PMID: 9057070. 10: Hasegawa K, Wakino S, Kanda T, Yoshioka K, Tatematsu S, Homma K, Takamatsu I, Sugano N, Hayashi K. Divergent action of calcium channel blockers on ATP- binding cassette protein expression. J Cardiovasc Pharmacol. 2005 Dec;46(6):787-93. doi: 10.1097/01.fjc.0000187976.60262.bf. PMID: 16306803. 11: Tian L, Jiang J, Huang Y, Xu L, Liu H, Li Y. Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20(19):2871-7. doi: 10.1002/rcm.2663. PMID: 16941544. 12: Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb- Mar;55(11-12):843-52. doi: 10.1007/s002280050706. PMID: 10805063. 13: Furukawa T, Nukada T, Namiki Y, Miyashita Y, Hatsuno K, Ueno Y, Yamakawa T, Isshiki T. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes. Eur J Pharmacol. 2009 Jun 24;613(1-3):100-7. doi: 10.1016/j.ejphar.2009.04.036. Epub 2009 May 3. PMID: 19401195. 14: Cummins DF. Newer calcium channel antagonists and the treatment of hypertension. Expert Opin Investig Drugs. 1999 Jul;8(7):1031-42. doi: 10.1517/13543784.8.7.1031. PMID: 15992104. 15: Uesawa Y, Mohri K. Quantitative structure-interaction relationship analysis of 1,4-dihydropyridine drugs in concomitant administration with grapefruit juice. Pharmazie. 2012 Mar;67(3):195-201. PMID: 22530299. 16: Okumura K, Ichihara K, Nagasaka M, Oda N, Tajima K. Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolites. Eur J Pharmacol. 1993 Apr 22;235(1):69-74. doi: 10.1016/0014-2999(93)90821-x. PMID: 8519282. 17: Miyoshi K, Kanda A, Miyake H, Ichihara K, Kamei H, Nagasaka M. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action. Eur J Pharmacol. 1993 Jul 20;238(2-3):139-48. doi: 10.1016/0014-2999(93)90841-5. PMID: 7691619. 18: Ohashi K, Sudo T, Sakamoto K, Tateishi T, Fujimura A, Kumagai Y, Shiga T, Ebihara A. Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. Int J Clin Pharmacol Ther Toxicol. 1992 Aug;30(8):271-4. PMID: 1526689. 19: Ichihara K, Okumura K, Mori H, Nagasaka M. Effects of MPC-1304, a novel Ca2+ entry blocker, on alpha-adrenoceptor-mediated pressor responses in pithed rats. Eur J Pharmacol. 1993 Jul 20;238(2-3):283-9. doi: 10.1016/0014-2999(93)90858-f. PMID: 8104810. 20: Miyoshi K, Kanda A, Nozawa Y, Nakano M, Miyake H. Regional vascular effects of MPC-1304, a novel dihydropyridine derivative, in conscious normotensive and spontaneously hypertensive rats. J Pharmacol Exp Ther. 1996 Jun;277(3):1328-36. PMID: 8667194.